Pfizer sells $7.8bn in Covid shots in the Q2, raises 2021 guidance on vaccine sales

Photo: AP

Pfizer said Wednesday it sold $7.8 billion in Covid-19 shots in the second quarter and raised its 2021 sales forecast for the vaccine to $33.5 billion from $26 billion, as the delta variant spreads and scientists debate whether people will need booster shots.

The company’s second-quarter financial results also beat Wall Street expectations on earnings and revenue. The company now expects full-year earnings in the range of $3.95 to $4.05 per share. That’s up from its prior range of $3.55 to $3.65 per share. It expects revenue in the range of $78 billion to $80 billion, up from its previous estimate of $70.5 billion to $72.5 billion.

“The second quarter was remarkable in a number of ways,” Pfizer CEO Albert Bourla said in a statement. “Most visibly, the speed and efficiency of our efforts with BioNTech to help vaccinate the world against COVID-19 have been unprecedented, with now more than a billion doses of BNT162b2 having been delivered globally.”

Pfizer’s other business units also saw strong sales growth. Revenue from its oncology unit rose by 19% year over year to $3.1 billion. The company’s hospital unit generated $2.2 billion in revenue, up 21% from the prior year. Its internal medicine unit grew by 5% from a year ago to $2.4 billion.

 
Pfizer said earlier this month it was seeing signs of waning immunity induced by its Covid vaccine with German drugmaker BioNTech, and planned to ask the Food and Drug Administration to authorize a booster dose. It also said it is developing a booster shot to target the delta variant.

In slides posted Wednesday alongside its earnings report, Pfizer said it could potentially file for an emergency use authorization for a booster dose with the FDA as early as August. It expects to begin clinical studies testing its delta variant vaccine in the same month.

It expects full approval for its two-dose vaccine by January 2022.

Similar articles

  • J&J booster jab raises effectiveness to 94%

    J&J booster jab raises effectiveness to 94%

    The pharmaceutical conglomerate Johnson and Johnson announced that a second shot of its Covid-19 vaccine given about two months after the first shot increased its effectiveness to 94% in the US against moderate to severe forms of the disease. That compares to only about 70% protection with a single dose, Reuters reported.

    7
  • BMW, Daimler face trials over carbon emissions targets

    BMW, Daimler face trials over carbon emissions targets

    German Daimler and BMW automotive producers found themselves under rapid legal fire over attempts to bring the two companies to court on charges linked to excessive carbon emissions. The heads of a German environmental NGO have sued both BMW and Daimler over their refusal to tighten carbon emissions targets and give up fossil fuel-emitting cars by 2030, Reuters reported. The NGO, Deutsche Umwelthilfe, confirmed that the lawsuits had been filed earlier this week.

    16
  • Boeing eyes large jet orders from European budget carriers

    Boeing eyes large jet orders from European budget carriers

    US Plane maker Boeing announced development plans based on increased demand for new jets on behalf of European low cost airlines. Boeing bets on Europe for the next 20 years, as airlines will have to replace their ageing planes with more fuel-efficient jets, Reuters elaborated. Boeing confirmed that it expected airlines in Europe to order 7,100 new single-aisle planes, mostly used for short haul trips, between 2021 and 2040, with low-cost specialists like Ryanair behind that demand.

    21